CytomX Therapeutics, Inc. (CTMX) 10-Year Financial Performance & Capital Metrics

CTMX •

HealthcareBiotechnologyDrug Discovery and Antibody Platforms

AboutCytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Show more

Revenue $138M +36.4%
EBITDA $27M +721.1%
Net Income $32M +5700.9%
EPS (Diluted) 0.38 +5035.1%
Gross Margin 100%
EBITDA Margin 19.38% +555.2%
Operating Margin 18.1% +382.5%
Net Margin 23.08% +4204.6%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)
✓Strong 5Y sales CAGR of 19.2%
✓Efficient asset utilization: 1.1x turnover

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 14.8% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y39.14%

5Y19.16%

3Y54.69%

TTM-10.26%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM102.59%

EPS CAGR

10Y-

5Y-

3Y-

TTM142.5%

ROCE

10Y Avg-21.16%

5Y Avg-14.55%

3Y Avg-0.41%

Latest61.99%

Peer Comparison

Drug Discovery and Antibody Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
REGNRegeneron Pharmaceuticals, Inc.	107.56B	781.67	18.84	0.99%	31.41%	14.41%	3.79%	0.09
CTMXCytomX Therapeutics, Inc.	430.14M	5.37	14.13	36.45%	24.66%	26.09%
PRTCPureTech Health plc	405.3M	16.77	8.39	44.98%	-495.91%	-8.53%		0.05
DNAGinkgo Bioworks Holdings, Inc.	327.53M	6.75	-1.20	-25.06%	-183.81%	-61.5%		0.82
BCYCBicycle Therapeutics plc	111.38M	5.73	-1.98	30.76%	-8.85%	-40.53%		0.01
CCCCC4 Therapeutics, Inc.	261.67M	2.70	-2.13	-100%		-40.92%		0.23
MOLNMolecular Partners AG	187.84M	5.02	-2.43	-29.38%	-10.87%	-63.06%		0.02
RXRXRecursion Pharmaceuticals, Inc.	1.94B	3.67	-2.55	26.92%	-8.65%	-57.01%		0.07

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	7.71M	15.04M	71.62M	59.5M	57.49M	68.43M	37.31M	53.16M	101.21M	138.1M
Revenue Growth %	51.9%	95.06%	376.12%	-16.92%	-3.38%	19.03%	-45.47%	42.48%	90.38%	36.45%
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	7.71M	15.04M	71.62M	59.5M	57.49M	68.43M	37.31M	53.16M	101.21M	138.1M
Gross Margin %	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Gross Profit Growth %	51.9%	95.06%	376.12%	-16.92%	-3.38%	19.03%	-45.47%	42.48%	90.38%	36.45%
Operating Expenses+	40.91M	74.63M	117.88M	137.38M	168.38M	148.97M	153.35M	154.5M	107.7M	113.11M
OpEx % of Revenue	530.54%	496.1%	164.59%	230.88%	292.9%	217.7%	411%	290.61%	106.41%	81.9%
Selling, General & Admin	12.56M	19.87M	25.61M	33.51M	36.77M	36.03M	39.16M	42.85M	30.02M	29.73M
SG&A % of Revenue	162.84%	132.11%	35.75%	56.32%	63.95%	52.66%	104.95%	80.6%	29.66%	21.52%
Research & Development	28.36M	54.76M	92.28M	103.87M	131.62M	112.94M	114.19M	111.65M	77.68M	83.38M
R&D % of Revenue	367.7%	363.99%	128.84%	174.56%	228.95%	165.05%	306.05%	210.01%	76.75%	60.38%
Other Operating Expenses	0	-69K	-27K	-68K	-135K	0	0	0	0	0
Operating Income+	-33.2M	-59.59M	-46.26M	-77.87M	-110.89M	-80.54M	-116.04M	-101.33M	-6.48M	25M
Operating Margin %	-430.54%	-396.1%	-64.59%	-130.88%	-192.9%	-117.7%	-311%	-190.61%	-6.41%	18.1%
Operating Income Growth %	-11.55%	-79.46%	22.37%	-68.34%	-42.4%	27.37%	-44.08%	12.67%	93.6%	485.49%
EBITDA+	-32M	-57.85M	-44.61M	-75.99M	-108.29M	-77.97M	-113.34M	-98.89M	-4.31M	26.76M
EBITDA Margin %	-414.9%	-384.58%	-62.29%	-127.71%	-188.37%	-113.94%	-303.75%	-186.02%	-4.26%	19.38%
EBITDA Growth %	-10.4%	-80.81%	22.88%	-70.33%	-42.51%	28%	-45.36%	12.74%	95.64%	721.1%
D&A (Non-Cash Add-back)	1.21M	1.73M	1.65M	1.88M	2.6M	2.57M	2.71M	2.44M	2.17M	1.77M
EBIT	-33.63M	-57.23M	-43.61M	-77.87M	-102.67M	-80.54M	-116.04M	-101.33M	-6.48M	25M
Net Interest Income+	-417K	736K	2.67M	7.64M	8.37M	1.84M	255K	1.68M	9.84M	7.14M
Interest Income	1.31M	2.42M	2.67M	7.64M	8.37M	1.84M	255K	1.68M	9.84M	7.14M
Interest Expense	1.73M	1.69M	0	0	0	0	0	0	0	0
Other Income/Expense	-2.16M	667K	2.65M	7.57M	8.23M	29.63M	172K	2.02M	9.81M	7.1M
Pretax Income+	-35.36M	-58.92M	-43.61M	-70.3M	-102.67M	-50.91M	-115.87M	-99.32M	3.32M	32.09M
Pretax Margin %	-458.56%	-391.67%	-60.89%	-118.15%	-178.58%	-74.4%	-310.54%	-186.82%	3.28%	23.24%
Income Tax+	10K	-19K	-513K	14.3M	-427K	13.91M	0	0	3.89M	224K
Effective Tax Rate %	100.03%	99.97%	98.82%	120.35%	99.58%	127.33%	100%	100%	-17.12%	99.3%
Net Income+	-35.37M	-58.9M	-43.1M	-84.6M	-102.24M	-64.82M	-115.87M	-99.32M	-569K	31.87M
Net Margin %	-458.69%	-391.54%	-60.17%	-142.19%	-177.84%	-94.73%	-310.54%	-186.82%	-0.56%	23.08%
Net Income Growth %	-16.71%	-66.51%	26.83%	-96.3%	-20.84%	36.6%	-78.76%	14.29%	99.43%	5700.88%
Net Income (Continuing)	-35.37M	-58.9M	-43.1M	-84.6M	-102.24M	-64.82M	-115.87M	-99.32M	-569K	31.87M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.00	-1.63	-1.16	-2.03	-2.26	-0.71	-1.26	-1.48	-0.01	0.38
EPS Growth %	-14.94%	-63%	28.83%	-75%	-11.33%	68.58%	-77.46%	-17.46%	99.48%	-
EPS (Basic)	-1.00	-1.63	-1.16	-2.03	-2.26	-0.71	-1.26	-1.48	-0.01	0.38
Diluted Shares Outstanding	35.49M	36.23M	37.17M	41.66M	45.34M	46.15M	64.15M	65.74M	73.81M	84.75M
Basic Shares Outstanding	35.48M	36.23M	37.17M	41.66M	45.34M	46.15M	64.15M	65.74M	73.81M	84.44M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	189.75M	188.15M	388.6M	445.48M	303.33M	324.01M	310.3M	237.1M	182.94M	107.31M
Cash & Short-Term Investments	186.71M	181.94M	374.11M	436.13M	296.14M	316.12M	305.23M	193.65M	174.51M	100.62M
Cash Only	59.82M	104.64M	177.55M	247.58M	188.43M	191.86M	205.53M	193.65M	17.17M	38.05M
Short-Term Investments	126.89M	77.29M	196.56M	188.55M	107.72M	124.26M	99.7M	0	157.34M	62.57M
Accounts Receivable	744K	2.31M	10.14M	97K	13K	798K	790K	35.99M	3.43M	3.1M
Days Sales Outstanding	35.21	56.12	51.67	0.59	0.08	4.26	7.73	247.07	12.38	8.2
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	2.3M	0	4.35M	9.25M	0	0	0	7.47M	5M	3.58M
Total Non-Current Assets+	7.46M	10.98M	9.04M	11.63M	37.95M	34.65M	29.11M	23.79M	18.86M	13.23M
Property, Plant & Equipment	3.48M	4.39M	4.22M	6.93M	32.75M	29.45M	25.32M	21.02M	16.18M	10.6M
Fixed Asset Turnover	2.22x	3.43x	16.98x	8.58x	1.76x	2.32x	1.47x	2.53x	6.26x	13.02x
Goodwill	949K	949K	949K	949K	949K	949K	949K	949K	949K	949K
Intangible Assets	1.75M	1.75M	1.6M	1.46M	1.31M	1.17M	1.02M	875K	729K	583K
Long-Term Investments	995K	0	917K	917K	0	0	0	0	0	0
Other Non-Current Assets	-115K	3.89M	957K	238K	2.93M	3.09M	1.82M	944K	1M	1.09M
Total Assets+	197.22M	199.13M	397.64M	457.11M	341.28M	358.66M	339.41M	260.89M	201.79M	120.53M
Asset Turnover	0.04x	0.08x	0.18x	0.13x	0.17x	0.19x	0.11x	0.20x	0.50x	1.15x
Asset Growth %	169.93%	0.97%	99.69%	14.95%	-25.34%	5.09%	-5.37%	-23.13%	-22.65%	-40.27%
Total Current Liabilities+	15.74M	35.77M	61.15M	97.91M	85.59M	68.11M	77.87M	152.61M	155.91M	85.77M
Accounts Payable	4.7M	6.6M	4.21M	5.13M	4.16M	3M	2.82M	2.81M	1.46M	1.09M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	6.13M	20.35M	40.56M	52.71M	51.38M	42.06M	40.82M	121.27M	132.27M	67.2M
Other Current Liabilities	2.07M	4.85M	11.86M	20.14M	0	0	0	0	9.44M	0
Current Ratio	12.06x	5.26x	6.36x	4.55x	3.54x	4.76x	3.98x	1.55x	1.17x	1.25x
Quick Ratio	12.06x	5.26x	6.36x	4.55x	3.54x	4.76x	3.98x	1.55x	1.17x	1.25x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	55.41M	84.88M	266.6M	228.32M	204.58M	298.33M	262M	194.03M	93.33M	35.22M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	24.87M	21.68M	18.06M	13.97M	9.38M	4.24M
Deferred Tax Liabilities	507K	513K	398K	1.14M	0	0	0	0	0	0
Other Non-Current Liabilities	198K	566K	1.9M	3.05M	850K	0	0	0	3.89M	4.12M
Total Liabilities	71.15M	120.65M	327.75M	326.23M	290.17M	366.44M	339.87M	346.64M	249.24M	120.99M
Total Debt+	0	0	0	0	27.68M	24.87M	21.67M	18.06M	13.97M	9.38M
Net Debt	-59.82M	-104.64M	-177.55M	-247.58M	-160.74M	-166.99M	-183.86M	-175.59M	-3.2M	-28.67M
Debt / Equity	-	-	-	-	0.54x	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	0.35x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-1.07x
Interest Coverage	-19.17x	-35.28x	-	-	-	-	-	-	-	-
Total Equity+	126.07M	78.48M	69.9M	130.88M	51.11M	-7.77M	-459K	-85.75M	-47.45M	-456K
Equity Growth %	260.51%	-37.75%	-10.94%	87.25%	-60.95%	-115.21%	94.1%	-18582.14%	44.67%	99.04%
Book Value per Share	3.55	2.17	1.88	3.14	1.13	-0.17	-0.01	-1.30	-0.64	-0.01
Total Shareholders' Equity	126.07M	78.48M	69.9M	130.88M	51.11M	-7.77M	-459K	-85.75M	-47.45M	-456K
Common Stock	1K	1K	1K	1K	1K	1K	1K	1K	1K	1K
Retained Earnings	-117.47M	-176.37M	-219.47M	-314.98M	-417.23M	-507.69M	-623.56M	-722.88M	-723.45M	-691.58M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-76K	-27K	-94K	-93K	57K	-47K	-242K	10K	95K	27K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-27.41M	-2.03M	170.37M	-75.52M	-140.48M	5.26M	-119.03M	-110.79M	-56.03M	-86.23M
Operating CF Margin %	-355.49%	-13.51%	237.87%	-126.92%	-244.36%	7.69%	-319.02%	-208.39%	-55.36%	-62.44%
Operating CF Growth %	-186.21%	92.59%	8484.5%	-144.33%	-86.01%	103.74%	-2363.38%	6.93%	49.42%	-53.89%
Net Income	-35.37M	-58.9M	-43.1M	-84.6M	-132.82M	-32.88M	-83.61M	-99.32M	-569K	31.87M
Depreciation & Amortization	1.21M	1.73M	1.65M	1.88M	2.6M	2.57M	2.71M	5.86M	2.17M	1.77M
Stock-Based Compensation	3.99M	10.1M	11.29M	16.88M	19.1M	14.79M	13.17M	0	0	7.67M
Deferred Taxes	8K	6K	-513K	0	0	-236K	272K	0	0	0
Other Non-Cash Items	3.01M	1.77M	11.09M	-1.7M	2.05M	2.89M	3.13M	13.33M	4.87M	-1.12M
Working Capital Changes	-248K	43.26M	189.97M	-7.98M	-31.41M	18.13M	-54.7M	-30.65M	-62.51M	-126.42M
Change in Receivables	1.13M	-1.57M	-7.83M	10.04M	84K	-785K	8K	-35.2M	32.55M	329K
Change in Inventory	1.81M	-253K	10.32M	19.91M	0	-11.12M	11.64M	0	0	0
Change in Payables	2.94M	1.76M	-2.44M	261K	-374K	-857K	-139K	68K	-1.43M	-297K
Cash from Investing+	-130.56M	45.86M	-121.27M	5.93M	79.7M	-18.72M	22.49M	98.26M	-150.67M	99.7M
Capital Expenditures	-1.59M	-2.18M	-1.56M	-3.79M	-3.5M	-2.31M	-1.61M	-1.74M	-840K	-310K
CapEx % of Revenue	20.67%	14.47%	2.18%	6.37%	6.08%	3.37%	4.31%	3.27%	0.83%	0.22%
Acquisitions	0	52K	121.27M	-5.93M	0	16.41M	-24.1M	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-817K	52K	-121.27M	5.93M	0	-16.41M	24.1M	0	0	0
Cash from Financing+	153.4M	996K	23.8M	139.62M	1.63M	16.89M	110.21M	648K	30.23M	7.52M
Debt Issued (Net)	-3.07M	78K	0	0	0	0	0	0	0	0
Equity Issued (Net)	1000K	0	1000K	1000K	0	1000K	1000K	648K	1000K	1000K
Dividends Paid	-6.71M	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	6.97M	918K	3.84M	5.03M	1.63M	5.61M	2.5M	0	0	613K
Net Change in Cash	-4.57M	44.82M	72.9M	70.03M	-59.15M	3.43M	13.67M	-11.88M	-176.48M	20.99M
Free Cash Flow+	-29.01M	-4.21M	168.81M	-79.31M	-143.98M	2.95M	-120.64M	-112.53M	-56.88M	-86.54M
FCF Margin %	-376.15%	-27.97%	235.7%	-133.29%	-250.44%	4.31%	-323.33%	-211.67%	-56.19%	-62.66%
FCF Growth %	-196.25%	85.49%	4111.74%	-146.98%	-81.54%	102.05%	-4189.49%	6.72%	49.46%	-52.16%
FCF per Share	-0.82	-0.12	4.54	-1.90	-3.18	0.06	-1.88	-1.71	-0.77	-1.02
FCF Conversion (FCF/Net Income)	0.78x	0.03x	-3.95x	0.89x	1.37x	-0.08x	1.03x	1.12x	98.48x	-2.71x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	13.06M	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-148.86%	-57.59%	-58.09%	-84.28%	-112.35%	-299.13%	-	-	-	-
Return on Invested Capital (ROIC)	-37.59%	-223%	-	-	-	-	-	-	-	-
Gross Margin	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Net Margin	-458.69%	-391.54%	-60.17%	-142.19%	-177.84%	-94.73%	-310.54%	-186.82%	-0.56%	23.08%
Debt / Equity	-	-	-	-	0.54x	-	-	-	-	-
Interest Coverage	-19.17x	-35.28x	-	-	-	-	-	-	-	-
FCF Conversion	0.78x	0.03x	-3.95x	0.89x	1.37x	-0.08x	1.03x	1.12x	98.48x	-2.71x
Revenue Growth	51.9%	95.06%	376.12%	-16.92%	-3.38%	19.03%	-45.47%	42.48%	90.38%	36.45%

US Stock Screener

...

CytomX Therapeutics, Inc. (CTMX) 10-Year Financial Performance & Capital Metrics

CTMX •

HealthcareBiotechnologyDrug Discovery and Antibody Platforms

Revenue $138M +36.4%
EBITDA $27M +721.1%
Net Income $32M +5700.9%
EPS (Diluted) 0.38 +5035.1%
Gross Margin 100%
EBITDA Margin 19.38% +555.2%
Operating Margin 18.1% +382.5%
Net Margin 23.08% +4204.6%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)
✓Strong 5Y sales CAGR of 19.2%
✓Efficient asset utilization: 1.1x turnover

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 14.8% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y39.14%

5Y19.16%

3Y54.69%

TTM-10.26%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM102.59%

EPS CAGR

10Y-

5Y-

3Y-

TTM142.5%

ROCE

10Y Avg-21.16%

5Y Avg-14.55%

3Y Avg-0.41%

Latest61.99%

Peer Comparison

Drug Discovery and Antibody Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
REGNRegeneron Pharmaceuticals, Inc.	107.56B	781.67	18.84	0.99%	31.41%	14.41%	3.79%	0.09
CTMXCytomX Therapeutics, Inc.	430.14M	5.37	14.13	36.45%	24.66%	26.09%
PRTCPureTech Health plc	405.3M	16.77	8.39	44.98%	-495.91%	-8.53%		0.05
DNAGinkgo Bioworks Holdings, Inc.	327.53M	6.75	-1.20	-25.06%	-183.81%	-61.5%		0.82
BCYCBicycle Therapeutics plc	111.38M	5.73	-1.98	30.76%	-8.85%	-40.53%		0.01
CCCCC4 Therapeutics, Inc.	261.67M	2.70	-2.13	-100%		-40.92%		0.23
MOLNMolecular Partners AG	187.84M	5.02	-2.43	-29.38%	-10.87%	-63.06%		0.02
RXRXRecursion Pharmaceuticals, Inc.	1.94B	3.67	-2.55	26.92%	-8.65%	-57.01%		0.07

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	7.71M	15.04M	71.62M	59.5M	57.49M	68.43M	37.31M	53.16M	101.21M	138.1M
Revenue Growth %	51.9%	95.06%	376.12%	-16.92%	-3.38%	19.03%	-45.47%	42.48%	90.38%	36.45%
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	7.71M	15.04M	71.62M	59.5M	57.49M	68.43M	37.31M	53.16M	101.21M	138.1M
Gross Margin %	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Gross Profit Growth %	51.9%	95.06%	376.12%	-16.92%	-3.38%	19.03%	-45.47%	42.48%	90.38%	36.45%
Operating Expenses+	40.91M	74.63M	117.88M	137.38M	168.38M	148.97M	153.35M	154.5M	107.7M	113.11M
OpEx % of Revenue	530.54%	496.1%	164.59%	230.88%	292.9%	217.7%	411%	290.61%	106.41%	81.9%
Selling, General & Admin	12.56M	19.87M	25.61M	33.51M	36.77M	36.03M	39.16M	42.85M	30.02M	29.73M
SG&A % of Revenue	162.84%	132.11%	35.75%	56.32%	63.95%	52.66%	104.95%	80.6%	29.66%	21.52%
Research & Development	28.36M	54.76M	92.28M	103.87M	131.62M	112.94M	114.19M	111.65M	77.68M	83.38M
R&D % of Revenue	367.7%	363.99%	128.84%	174.56%	228.95%	165.05%	306.05%	210.01%	76.75%	60.38%
Other Operating Expenses	0	-69K	-27K	-68K	-135K	0	0	0	0	0
Operating Income+	-33.2M	-59.59M	-46.26M	-77.87M	-110.89M	-80.54M	-116.04M	-101.33M	-6.48M	25M
Operating Margin %	-430.54%	-396.1%	-64.59%	-130.88%	-192.9%	-117.7%	-311%	-190.61%	-6.41%	18.1%
Operating Income Growth %	-11.55%	-79.46%	22.37%	-68.34%	-42.4%	27.37%	-44.08%	12.67%	93.6%	485.49%
EBITDA+	-32M	-57.85M	-44.61M	-75.99M	-108.29M	-77.97M	-113.34M	-98.89M	-4.31M	26.76M
EBITDA Margin %	-414.9%	-384.58%	-62.29%	-127.71%	-188.37%	-113.94%	-303.75%	-186.02%	-4.26%	19.38%
EBITDA Growth %	-10.4%	-80.81%	22.88%	-70.33%	-42.51%	28%	-45.36%	12.74%	95.64%	721.1%
D&A (Non-Cash Add-back)	1.21M	1.73M	1.65M	1.88M	2.6M	2.57M	2.71M	2.44M	2.17M	1.77M
EBIT	-33.63M	-57.23M	-43.61M	-77.87M	-102.67M	-80.54M	-116.04M	-101.33M	-6.48M	25M
Net Interest Income+	-417K	736K	2.67M	7.64M	8.37M	1.84M	255K	1.68M	9.84M	7.14M
Interest Income	1.31M	2.42M	2.67M	7.64M	8.37M	1.84M	255K	1.68M	9.84M	7.14M
Interest Expense	1.73M	1.69M	0	0	0	0	0	0	0	0
Other Income/Expense	-2.16M	667K	2.65M	7.57M	8.23M	29.63M	172K	2.02M	9.81M	7.1M
Pretax Income+	-35.36M	-58.92M	-43.61M	-70.3M	-102.67M	-50.91M	-115.87M	-99.32M	3.32M	32.09M
Pretax Margin %	-458.56%	-391.67%	-60.89%	-118.15%	-178.58%	-74.4%	-310.54%	-186.82%	3.28%	23.24%
Income Tax+	10K	-19K	-513K	14.3M	-427K	13.91M	0	0	3.89M	224K
Effective Tax Rate %	100.03%	99.97%	98.82%	120.35%	99.58%	127.33%	100%	100%	-17.12%	99.3%
Net Income+	-35.37M	-58.9M	-43.1M	-84.6M	-102.24M	-64.82M	-115.87M	-99.32M	-569K	31.87M
Net Margin %	-458.69%	-391.54%	-60.17%	-142.19%	-177.84%	-94.73%	-310.54%	-186.82%	-0.56%	23.08%
Net Income Growth %	-16.71%	-66.51%	26.83%	-96.3%	-20.84%	36.6%	-78.76%	14.29%	99.43%	5700.88%
Net Income (Continuing)	-35.37M	-58.9M	-43.1M	-84.6M	-102.24M	-64.82M	-115.87M	-99.32M	-569K	31.87M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.00	-1.63	-1.16	-2.03	-2.26	-0.71	-1.26	-1.48	-0.01	0.38
EPS Growth %	-14.94%	-63%	28.83%	-75%	-11.33%	68.58%	-77.46%	-17.46%	99.48%	-
EPS (Basic)	-1.00	-1.63	-1.16	-2.03	-2.26	-0.71	-1.26	-1.48	-0.01	0.38
Diluted Shares Outstanding	35.49M	36.23M	37.17M	41.66M	45.34M	46.15M	64.15M	65.74M	73.81M	84.75M
Basic Shares Outstanding	35.48M	36.23M	37.17M	41.66M	45.34M	46.15M	64.15M	65.74M	73.81M	84.44M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	189.75M	188.15M	388.6M	445.48M	303.33M	324.01M	310.3M	237.1M	182.94M	107.31M
Cash & Short-Term Investments	186.71M	181.94M	374.11M	436.13M	296.14M	316.12M	305.23M	193.65M	174.51M	100.62M
Cash Only	59.82M	104.64M	177.55M	247.58M	188.43M	191.86M	205.53M	193.65M	17.17M	38.05M
Short-Term Investments	126.89M	77.29M	196.56M	188.55M	107.72M	124.26M	99.7M	0	157.34M	62.57M
Accounts Receivable	744K	2.31M	10.14M	97K	13K	798K	790K	35.99M	3.43M	3.1M
Days Sales Outstanding	35.21	56.12	51.67	0.59	0.08	4.26	7.73	247.07	12.38	8.2
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	2.3M	0	4.35M	9.25M	0	0	0	7.47M	5M	3.58M
Total Non-Current Assets+	7.46M	10.98M	9.04M	11.63M	37.95M	34.65M	29.11M	23.79M	18.86M	13.23M
Property, Plant & Equipment	3.48M	4.39M	4.22M	6.93M	32.75M	29.45M	25.32M	21.02M	16.18M	10.6M
Fixed Asset Turnover	2.22x	3.43x	16.98x	8.58x	1.76x	2.32x	1.47x	2.53x	6.26x	13.02x
Goodwill	949K	949K	949K	949K	949K	949K	949K	949K	949K	949K
Intangible Assets	1.75M	1.75M	1.6M	1.46M	1.31M	1.17M	1.02M	875K	729K	583K
Long-Term Investments	995K	0	917K	917K	0	0	0	0	0	0
Other Non-Current Assets	-115K	3.89M	957K	238K	2.93M	3.09M	1.82M	944K	1M	1.09M
Total Assets+	197.22M	199.13M	397.64M	457.11M	341.28M	358.66M	339.41M	260.89M	201.79M	120.53M
Asset Turnover	0.04x	0.08x	0.18x	0.13x	0.17x	0.19x	0.11x	0.20x	0.50x	1.15x
Asset Growth %	169.93%	0.97%	99.69%	14.95%	-25.34%	5.09%	-5.37%	-23.13%	-22.65%	-40.27%
Total Current Liabilities+	15.74M	35.77M	61.15M	97.91M	85.59M	68.11M	77.87M	152.61M	155.91M	85.77M
Accounts Payable	4.7M	6.6M	4.21M	5.13M	4.16M	3M	2.82M	2.81M	1.46M	1.09M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	6.13M	20.35M	40.56M	52.71M	51.38M	42.06M	40.82M	121.27M	132.27M	67.2M
Other Current Liabilities	2.07M	4.85M	11.86M	20.14M	0	0	0	0	9.44M	0
Current Ratio	12.06x	5.26x	6.36x	4.55x	3.54x	4.76x	3.98x	1.55x	1.17x	1.25x
Quick Ratio	12.06x	5.26x	6.36x	4.55x	3.54x	4.76x	3.98x	1.55x	1.17x	1.25x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	55.41M	84.88M	266.6M	228.32M	204.58M	298.33M	262M	194.03M	93.33M	35.22M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	24.87M	21.68M	18.06M	13.97M	9.38M	4.24M
Deferred Tax Liabilities	507K	513K	398K	1.14M	0	0	0	0	0	0
Other Non-Current Liabilities	198K	566K	1.9M	3.05M	850K	0	0	0	3.89M	4.12M
Total Liabilities	71.15M	120.65M	327.75M	326.23M	290.17M	366.44M	339.87M	346.64M	249.24M	120.99M
Total Debt+	0	0	0	0	27.68M	24.87M	21.67M	18.06M	13.97M	9.38M
Net Debt	-59.82M	-104.64M	-177.55M	-247.58M	-160.74M	-166.99M	-183.86M	-175.59M	-3.2M	-28.67M
Debt / Equity	-	-	-	-	0.54x	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	0.35x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-1.07x
Interest Coverage	-19.17x	-35.28x	-	-	-	-	-	-	-	-
Total Equity+	126.07M	78.48M	69.9M	130.88M	51.11M	-7.77M	-459K	-85.75M	-47.45M	-456K
Equity Growth %	260.51%	-37.75%	-10.94%	87.25%	-60.95%	-115.21%	94.1%	-18582.14%	44.67%	99.04%
Book Value per Share	3.55	2.17	1.88	3.14	1.13	-0.17	-0.01	-1.30	-0.64	-0.01
Total Shareholders' Equity	126.07M	78.48M	69.9M	130.88M	51.11M	-7.77M	-459K	-85.75M	-47.45M	-456K
Common Stock	1K	1K	1K	1K	1K	1K	1K	1K	1K	1K
Retained Earnings	-117.47M	-176.37M	-219.47M	-314.98M	-417.23M	-507.69M	-623.56M	-722.88M	-723.45M	-691.58M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-76K	-27K	-94K	-93K	57K	-47K	-242K	10K	95K	27K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-27.41M	-2.03M	170.37M	-75.52M	-140.48M	5.26M	-119.03M	-110.79M	-56.03M	-86.23M
Operating CF Margin %	-355.49%	-13.51%	237.87%	-126.92%	-244.36%	7.69%	-319.02%	-208.39%	-55.36%	-62.44%
Operating CF Growth %	-186.21%	92.59%	8484.5%	-144.33%	-86.01%	103.74%	-2363.38%	6.93%	49.42%	-53.89%
Net Income	-35.37M	-58.9M	-43.1M	-84.6M	-132.82M	-32.88M	-83.61M	-99.32M	-569K	31.87M
Depreciation & Amortization	1.21M	1.73M	1.65M	1.88M	2.6M	2.57M	2.71M	5.86M	2.17M	1.77M
Stock-Based Compensation	3.99M	10.1M	11.29M	16.88M	19.1M	14.79M	13.17M	0	0	7.67M
Deferred Taxes	8K	6K	-513K	0	0	-236K	272K	0	0	0
Other Non-Cash Items	3.01M	1.77M	11.09M	-1.7M	2.05M	2.89M	3.13M	13.33M	4.87M	-1.12M
Working Capital Changes	-248K	43.26M	189.97M	-7.98M	-31.41M	18.13M	-54.7M	-30.65M	-62.51M	-126.42M
Change in Receivables	1.13M	-1.57M	-7.83M	10.04M	84K	-785K	8K	-35.2M	32.55M	329K
Change in Inventory	1.81M	-253K	10.32M	19.91M	0	-11.12M	11.64M	0	0	0
Change in Payables	2.94M	1.76M	-2.44M	261K	-374K	-857K	-139K	68K	-1.43M	-297K
Cash from Investing+	-130.56M	45.86M	-121.27M	5.93M	79.7M	-18.72M	22.49M	98.26M	-150.67M	99.7M
Capital Expenditures	-1.59M	-2.18M	-1.56M	-3.79M	-3.5M	-2.31M	-1.61M	-1.74M	-840K	-310K
CapEx % of Revenue	20.67%	14.47%	2.18%	6.37%	6.08%	3.37%	4.31%	3.27%	0.83%	0.22%
Acquisitions	0	52K	121.27M	-5.93M	0	16.41M	-24.1M	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-817K	52K	-121.27M	5.93M	0	-16.41M	24.1M	0	0	0
Cash from Financing+	153.4M	996K	23.8M	139.62M	1.63M	16.89M	110.21M	648K	30.23M	7.52M
Debt Issued (Net)	-3.07M	78K	0	0	0	0	0	0	0	0
Equity Issued (Net)	1000K	0	1000K	1000K	0	1000K	1000K	648K	1000K	1000K
Dividends Paid	-6.71M	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	6.97M	918K	3.84M	5.03M	1.63M	5.61M	2.5M	0	0	613K
Net Change in Cash	-4.57M	44.82M	72.9M	70.03M	-59.15M	3.43M	13.67M	-11.88M	-176.48M	20.99M
Free Cash Flow+	-29.01M	-4.21M	168.81M	-79.31M	-143.98M	2.95M	-120.64M	-112.53M	-56.88M	-86.54M
FCF Margin %	-376.15%	-27.97%	235.7%	-133.29%	-250.44%	4.31%	-323.33%	-211.67%	-56.19%	-62.66%
FCF Growth %	-196.25%	85.49%	4111.74%	-146.98%	-81.54%	102.05%	-4189.49%	6.72%	49.46%	-52.16%
FCF per Share	-0.82	-0.12	4.54	-1.90	-3.18	0.06	-1.88	-1.71	-0.77	-1.02
FCF Conversion (FCF/Net Income)	0.78x	0.03x	-3.95x	0.89x	1.37x	-0.08x	1.03x	1.12x	98.48x	-2.71x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	13.06M	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-148.86%	-57.59%	-58.09%	-84.28%	-112.35%	-299.13%	-	-	-	-
Return on Invested Capital (ROIC)	-37.59%	-223%	-	-	-	-	-	-	-	-
Gross Margin	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Net Margin	-458.69%	-391.54%	-60.17%	-142.19%	-177.84%	-94.73%	-310.54%	-186.82%	-0.56%	23.08%
Debt / Equity	-	-	-	-	0.54x	-	-	-	-	-
Interest Coverage	-19.17x	-35.28x	-	-	-	-	-	-	-	-
FCF Conversion	0.78x	0.03x	-3.95x	0.89x	1.37x	-0.08x	1.03x	1.12x	98.48x	-2.71x
Revenue Growth	51.9%	95.06%	376.12%	-16.92%	-3.38%	19.03%	-45.47%	42.48%	90.38%	36.45%

CytomX Therapeutics, Inc. (CTMX) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare CTMX vs Peers

vs REGN

vs CNTA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

CytomX Therapeutics, Inc. (CTMX) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare CTMX vs Peers

vs REGN

vs CNTA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios